期刊文献+

血清YKL-40蛋白水平与非肌层浸润性膀胱癌复发的临床关系研究 被引量:7

Clinical correlation between serum YKL-40 protein level and the recurrence of non muscle-invasive bladder cancer
下载PDF
导出
摘要 目的:探讨患者血清YKL-40蛋白水平与非肌层浸润性膀胱癌(non muscle-invasive bladder cancer,NMIBC)复发的临床关系。方法:选取76例NMIBC患者,其中34例为术后随访两年内确诊复发患者、42例为术后随访两年未见复发患者,及健康对照组31例,采取清晨血清样本,采用酶联接免疫吸附剂测定法(ELISA)检测患者血清中YKL-40水平。结果:NMIBC患者血清YKL-40水平显著高于健康对照组(P<0.001),同时,NMIBC复发组患者血清YKL-40水平高于非复发组(P=0.001)。结论:血清YKL-40蛋白水平在非肌层浸润性膀胱癌复发中有着较高的临床诊断价值,可作为监测患者术后复发的一种新分子标志物,为患者术后相关后续治疗提供参考。 Objective: The aim of this study was to further understand the correlation between serum YKL-40 protein level and recurrence of non muscle-invasive bladder cancer (NMIBC). Methods: Totally, 76 patients of NMIBC and 31 healthy volunteers were recruited in this study. After two years follow-up, 34 patients were found with recurrence by cystoscope. Serum YKL-40 protein levels of all these patients were analysed by using Enzyme- linked immunosorbent assay (ELISA) methods. Data analyses and ROC curve were performed in SPSS. All values are two tailed. Results: Serum YKL-40 protein levels were significantly higher in patients with bladder cancercompared with controls (P〈0.001). Serum YKL-40 protein levels were found to be higher in patients with recurrent NMIBC compared with patients with non recurrent bladder cancer (P=0.001). Conclusion: Serum YKL-40 protein could be a reliable molecular marker for diagnosis of recurrence of NMIBC. Serum YKL-40 protein level could provide a good value of guide for postoperative treatment.
出处 《临床与病理杂志》 CAS 2015年第4期598-602,共5页 Journal of Clinical and Pathological Research
基金 上海市自然科学基金面上项目(14ZR1432300)~~
关键词 YKL-40 非肌层浸润性膀胱癌 复发 血清 YKL-40 non muscle-invasive bladder cancer recurrence serum
  • 相关文献

参考文献1

二级参考文献12

  • 1杨国奋,李晓明,谢丹,朝葵,蔡鹏宇.卵巢癌组织中clusterin蛋白表达和细胞凋亡检测[J].中国肿瘤临床,2007,34(12):674-676. 被引量:17
  • 2Walsh JM, Dolan NC, Charney P, et al. Update in womenE's health [J]. Ann Int Med, 2000, 133(10):808-814.
  • 3MenonU, Jacobs IJ. Recent developments in ovarian cancer screening [J]. Curr Opin Obstet Gynaecol, 2000, 12(1) : 39-42.
  • 4Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40 [J]. J Clin Oncl, 2004,22(16) : 3330-3339.
  • 5Johansen JS, Drivsholm L, Price PA, et al. High serum YKL- 40 level in patients with small cell lung cancer is related to early death [J]. Lung Cancer, 2004,46(3) :333-340.
  • 6Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer [J]. Gynecol Oncol, 2007,104(2):435-442.
  • 7Lau SH, Sham JS, Xie D, et al. Clusterin plays an important role in hepatocellular carcinoma metastasis [J]. Oncogene, 2006,25(8) : 1242-1250.
  • 8Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer [J]. Dan Med Bull, 2006,53(2):172-209.
  • 9Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients? [J]. Cancer Epidemiol Biomarkers Prov, 2006,15(2) : 194-202.
  • 10Dehn H, Hogdall E V, Johansen JS, et al. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer [J]. Acta Obstec Gynecol Stand, 2003,82(3) : 287-293.

共引文献11

同被引文献33

  • 1Avgeris M,Mavridis K,Tokas T,et al.Uncovering the clinical utility of miR-143,miR-145and miR-224for predicting the survival of bladder cancer patients following treatment[J].Carcinogenesis,2015,36(5):528-537.
  • 2Tolle A,Jung M,Rabenhorst S,et al.Identification of microRNAs in blood and urine as tumour markers for the detection of urinarybladder cancer[J].Oncol Rep,2013,30(4):1949-1956.
  • 3Khorrami MH,Hadi M,Gharaati MR,et al.E-cadherin expression as a prognostic factor in transitional cell carcinoma of the bladder after transurethral resection[J].Urol J,2012,9(3):581-585.
  • 4Simpson GR,Horvath A,Annels NE,et al.C ombination of a fusogenic glycoprotein,pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer[J].Br J Cancer,2012,106(3):496-507.
  • 5Lima L,Oliveira D,Tavares A,et al.The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure[J].Urol Oncol,2014,32(4):449-457.
  • 6Kandeel W,Abdelal A,Elmohamady BN,et al.A comparative study between full-dose and half-dose intravesical immune bacille Calmette-Guérin injection in the management of superficial bladder cancer[J].Arab J Urol,2015,13(4):233-237.
  • 7Jaiswal PK,Singh V,Srivastava P,et al.Association of IL-12 ,IL-18variants and serum IL-18with bladder cancer susceptibility in North Indian population[J].Gene,2013,519(1):128-134.
  • 8Tadin T,Sotosek S,Raheli'c D,et al.Diagnostic accuracy of ultrasound T-staging of the urinary bladder cancer in comparison with histology in elderly patients[J].Coll Antropol,2014,38(4):1123-1126.
  • 9Pérez-Jacoiste Asín MA,Fernández-Ruiz M,Lpez-Medrano F,et al.Bacillus Calmette-Guérin(BCG)infection following intravesical BCG administration as adjunctive therapy for bladder cancer:incidence,risk factors,and outcome in a single-institution series and review of the literature[J].Medicine(Baltimore),2014,93(17):236-254.
  • 10Gorodkiewicz E,Guszcz T,Roszkowska-Jakimiec W,et al.Cathepsin D serum and urine concentration in superficial and invasive transitional bladder canceras determined by surface plasmon resonance imaging[J].Oncol Lett,2014,8(3):1323-1327.

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部